J. Cullen

发表

Silencing of lactotransferrin expression by methylation in prostate cancer progression

V. Srikantan, S. Srivastava, I. Sesterhenn, 2007, Cancer biology & therapy.

Machine learning algorithms to estimate 10-Year survival in patients with bone metastases due to prostate cancer: toward a disease-specific survival estimation tool

J. Forsberg, R. Wedin, Yongmei Chen, 2022, BMC cancer.

Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells

Arun K. Srivastava, Hua Li, J. Cullen, 2019, International journal of molecular sciences.

Anterior tumors of the prostate: clinicopathological features and outcomes

I. Sesterhenn, A. Dobi, J. Cullen, 2013, Prostate Cancer and Prostatic Disease.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men

Jonathan E. Shoag, Jim C Hu, D. Spratt, 2022, NEJM Evidence.

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression

Thomas L. Fillmore, Richard D. Smith, S. Srivastava, 2020, Cancers.

Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.

P. Kantoff, T. Rebbeck, W. Kelly, 2020, European urology.

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.

Jonathan E. Shoag, Jim C Hu, D. Spratt, 2022, NEJM evidence.

Effect of obesity on prostate‐specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group‐American Society for Therapeutic Radiation and Oncology (RTOG‐ASTRO) Phoenix consensus definition

S. Stroup, J. L'esperance, J. Cullen, 2007, Cancer.

Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers

S. Srivastava, I. Sesterhenn, Hua Li, 2021, Frontiers in Oncology.

A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic.

C. Porter, L. Hurwitz, J. Cullen, 2016, Urologic oncology.

Racial and ethnic differences in lymph node examination after colon cancer resection do not completely explain disparities in mortality

S. Wren, J. Cullen, K. Rhoads, 2012, Cancer.

Race‐specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990–2017

A. D'Amico, T. Rebbeck, T. Brand, 2022, Cancer medicine.

Race‐specific prostate cancer outcomes in a cohort of low and favorable‐intermediate risk patients who underwent external beam radiation therapy from 1990 to 2017

A. D'Amico, T. Brand, Samantha Streicher, 2022, Cancer medicine.

Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.

Timothy F. Donahue, J. Coleman, D. Danila, 2017, Urologic oncology.

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

T. Brand, A. Metwalli, Yongmei Chen, 2014, Urologic oncology.

Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients with and without Prostate Cancer

T. Brand, C. Porter, S. Stroup, 2019, The Journal of urology.

Differences in the frequency of ERG oncoprotein expression between index tumors of Caucasian American and African American prostate cancer patients

S. Srivastava, S. Perner, D. Pfister, 2012 .

Reply to Prostate cancer multidisciplinary clinic and decisional regret: Looking for a longer follow‐up

L. Hurwitz, J. Cullen, 2017, Cancer.

A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.

Jack A. Taylor, T. Sellers, J. Carpten, 2020, European urology.

A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.

Jack A. Taylor, T. Sellers, J. Carpten, 2022, European urology.

Neighborhood Socioeconomic Disadvantage Associated with Increased 90-day Mortality Following Radical Cystectomy.

J. Kaouk, G. Haber, C. Weight, 2021, Urology.

Evaluating Factors Associated With Continuous Glucose Monitoring Utilization With the Type 1 Diabetes Exchange Registry.

C. Drummond, S. Markt, J. Cullen, 2022, Journal of diabetes science and technology.

Testosterone recovery after polytrauma and scrotal injury in patients from Operation Enduring Freedom and Operation Iraqi Freedom.

Yongmei Chen, J. Jezior, J. Cullen, 2013, The Journal of urology.

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer

Z. Szallasi, S. Srivastava, Hua Li, 2019, Cancers.

A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy.

K. Badiozamani, T. Brand, C. Porter, 2020, Urologic oncology.

Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival

J. Barnholtz-Sloan, N. Hamerschlak, K. Waite, 2022, Cancer medicine.

5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis

M. Kattan, E. Klein, L. Jehi, 2021, The Journal of urology.

A prospective, randomized, placebo‐controlled trial of on‐Demand vs. nightly sildenafil citrate as assessed by Rigiscan and the international index of erectile function

T. Lue, L. Hurwitz, J. Cullen, 2016, Andrology.

Racial disparities in breast cancer treatment patterns and treatment related adverse events

J. Barnholtz-Sloan, N. Hamerschlak, K. Waite, 2023, Scientific Reports.

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence

S. Srivastava, I. Sesterhenn, S. Srivastava, 2019, Oncotarget.

Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2008, Modern Pathology.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

S. Ambs, S. Srivastava, I. Sesterhenn, 2018, Prostate Cancer and Prostatic Diseases.

A Urine Exosome Gene Expression Panel Distinguishes Between Indolent and Aggressive Prostate Cancers at Biopsy.

S. Srivastava, I. Sesterhenn, S. Srivastava, 2020, The Journal of urology.

Prognostic features of Annexin A2 expression in prostate cancer.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2020, Pathology.

Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer

Chen Sun, S. Srivastava, I. Sesterhenn, 2008, Clinical Cancer Research.

Genomic alterations of Tenascin C in highly aggressive prostate cancer: a meta-analysis

M. Kiebish, A. Srinivasan, Prachi Mishra, 2019, Genes & cancer.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag

S. Srivastava, I. Sesterhenn, S. Srivastava, 2016, Genes & cancer.

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression

Cara C. Schafer, J. Moul, S. Srivastava, 2022, Scientific Reports.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

S. Ambs, S. Srivastava, I. Sesterhenn, 2018, Prostate Cancer and Prostatic Diseases.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature Genetics.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature genetics.

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

P. Febbo, M. Cooperberg, P. Carroll, 2016, Urology.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2008, The Journal of urology.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Nan Zhang, Amina Ali, P. Febbo, 2015, European urology.

Title Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate

P. Febbo, M. Cooperberg, P. Carroll, 2016 .

Predominance of ERG-negative high-grade prostate cancers in African American men.

S. Srivastava, I. Sesterhenn, S. Srivastava, 2014, Molecular and clinical oncology.

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

B. Kramer, M. Khoury, K. Goddard, 2015, Journal of the National Cancer Institute.

Prostate Cancer A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low-and Intermediate-risk Prostate Cancer

P. Febbo, S. Srivastava, I. Sesterhenn, 2015 .

Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat.

Yongmei Chen, D. Mcleod, M. Colombo, 2013, Urologic oncology.

PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

B. Trock, A. Partin, P. Walsh, 2019, Clinical genitourinary cancer.

Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes

S. Srivastava, I. Sesterhenn, H. Pollard, 2022, Nature Communications.

Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.

Jacob M. Keaton, Jack A. Taylor, J. Witte, 2023, European urology.

Cardiovascular Toxicities of Androgen Deprivation Therapy

N. Desai, Jorge A. Garcia, N. Weintraub, 2021, Current Treatment Options in Oncology.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

S. Srivastava, I. Sesterhenn, S. Perner, 2012, Urology.

Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort

T. Brand, Yongmei Chen, D. Mcleod, 2011, Prostate cancer.

Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

Jack A. Taylor, O. Andreassen, A. Dale, 2021, Prostate Cancer and Prostatic Diseases.

African‐specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

Jack A. Taylor, O. Andreassen, R. Eeles, 2020, medRxiv.

Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer

Z. Szallasi, S. Srivastava, Hua Li, 2020, Oncotarget.

Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy.

M. Terris, S. Freedland, C. Amling, 2007, The Journal of urology.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2017, European urology focus.

Prostate cancer screening at National Cancer Institute comprehensive and clinical cancer centers.

M. Schwartz, J. Cullen, C. Ahaghotu, 2004, Journal of the National Cancer Institute.

Area-level socioeconomic status is positively correlated with glioblastoma incidence and prognosis in the United States

Jennifer S. Yu, J. Cullen, E. Murphy, 2023, Frontiers in Oncology.

Race and overall survival in men diagnosed with prostate cancer in the Department of Defense Military Health System, 1990–2010

C. Byrne, J. Cullen, J. Rusiecki, 2019, Cancer Causes & Control.

Race and overall survival in men diagnosed with prostate cancer in the Department of Defense Military Health System, 1990–2010

C. Byrne, J. Cullen, J. Rusiecki, 2019, Cancer Causes & Control.

Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes.

Yongmei Chen, D. Mcleod, J. Cullen, 2011, The Journal of urology.

The burden of prostate cancer in Asian nations

Yongmei Chen, D. Mcleod, M. Colombo, 2012, Journal of carcinogenesis.

Prospective quality‐of‐life outcomes for low‐risk prostate cancer: Active surveillance versus radical prostatectomy

Ruth Etzioni, T. Brand, C. Jeldres, 2015, Cancer.

Longitudinal regret after treatment for low‐ and intermediate‐risk prostate cancer

C. Porter, L. Hurwitz, J. Cullen, 2017, Cancer.

Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies

B. Trock, Jiji Jiang, M. Eisenberger, 2021, The Journal of urology.

Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7.

Yongmei Chen, J. Cullen, D. Soderdahl, 2010, Urologic oncology.

Prostate cancer in men less than the age of 50: a comparison of race and outcomes.

Yongmei Chen, D. Mcleod, J. Cullen, 2011, Urology.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2008, Urology.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.

Ashutosh Kumar Singh, K. Stange, H. Carraway, 2023, The oncologist.

Time to an undetectable prostate‐specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer‐specific mortality

A. D'Amico, Ming-Hui Chen, D. Mcleod, 2007, Cancer.

Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer.

T. Brand, C. Porter, J. L'esperance, 2016, The Journal of urology.

MP14-05 A PROSPECTIVE COHORT STUDY OF TREATMENT DECISION-MAKING FOR PROSTATE CANCER FOLLOWING PARTICIPATION IN A MULTI-DISCIPLINARY CLINIC

L. Hurwitz, J. Cullen, I. Rosner, 2015 .

The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer.

S. V. D. Eeden, J. Cullen, J. Shan, 2020, Urology.

Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).

Kathleen W. Zhang, Arjun K. Ghosh, N. Desai, 2021, The Journal of urology.

Race, tumor location, and disease progression among low‐risk prostate cancer patients

I. Sesterhenn, Yongmei Chen, G. Williams, 2020, Cancer medicine.

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men

S. Srivastava, G. Petrovics, A. Dobi, 2023, Biomedicines.

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer

Qiyuan Li, S. Srivastava, M. Freedman, 2020, Oncotarget.

D. Mcleod, J. Cullen, S. Brassell, 2013, Urologic oncology.

Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2007, Urology.

Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic.

L. Black, J. Cullen, S. Brassell, 2010, Urology.

Decade-long Trends in Prostate Cancer Incidence and Mortality in Poland, 1999–2012

D. Mcleod, L. Hurwitz, J. Cullen, 2018 .

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Jeonifer M. Garren, S. Srivastava, E. Diamandis, 2021, Scientific Reports.

Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with HIV

J. Pink, P. Fu, S. Gerson, 2023, Cancer medicine.

152 ALL-CAUSE MORTALITY AMONG MILITARY HEALTH CARE BENEFICIARIES WITH PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE

S. Srivastava, Yongmei Chen, D. Mcleod, 2011 .

Allostatic load and cardiovascular outcomes in males with prostate cancer

M. Terris, S. Coughlin, J. Barnholtz-Sloan, 2023, JNCI cancer spectrum.

A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.

T. Brand, C. Porter, L. Hurwitz, 2017, Urologic oncology.

Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

T. Brand, A. Metwalli, Yongmei Chen, 2014, Urologic oncology.

Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy

A. Metwalli, Yongmei Chen, L. Hurwitz, 2018, BioMed research international.

Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat.

Yongmei Chen, D. Mcleod, J. Cullen, 2013, Urologic oncology.

Prostate‐specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer

A. D'Amico, Yongmei Chen, D. Mcleod, 2007, Cancer.

Prostate cancer in men less than the age of 50: a comparison of race and outcomes.

Yongmei Chen, D. Mcleod, J. Cullen, 2011, Urology.

Abstract 3517: A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry

Jack A. Taylor, T. Sellers, J. Carpten, 2020, Epidemiology.

Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in Black and White Men with Clinically Localized Prostate Cancer.

P. Carroll, E. Klein, J. Mohler, 2020, The Journal of urology.